Results 101 to 110 of about 12,008,318 (406)

Metabolomics study of osteopetrosis caused by CLCN7 mutation reveals novel pathway and potential biomarkers

Frontiers in Endocrinology
ObjectiveCLCN7 mutation caused abnormal osteoclasts, resulting in osteopetrosis. Depending on the type of mutation, CLCN7 mutations can lead to severe or relatively benign forms of osteopetrosis.
Xi Chen, Ziyuan Wang, Wenzhen Fu, Zhe Wei, Jiemei Gu, Chun Wang, Zhenlin Zhang, Zhenlin Zhang, Xiangtian Yu, Weiwei Hu   +9 more
doaj   +1 more source

Osteocytes and mechanical loading: The Wnt connection [PDF]

, 2019
Bone adapts to the mechanical forces that it experiences. Orthodontic tooth movement harnesses the cell‐ and tissue‐level properties of mechanotransduction to achieve alignment and reorganization of the dentition.
Ahn Y, Balemans W, Cui Y, Fu HD, Gong Y, Harris SE, Leupin O, Lim WH, Little RD, Loots GG, Niziolek PJ, Odagaki N, Ohazama A, Poole KE, Robling AG, Sawakami K, Saxon LK, Semenov M, Tu X, Van Wesenbeeck L, Zhao L, Zong Y   +21 more
core   +1 more source

Genetic approaches to metabolic bone diseases

British Journal of Clinical Pharmacology, 2018
Metabolic bone diseases comprise a diverse group of disorders characterized by alterations in skeletal homeostasis, and are often associated with abnormal circulating concentrations of calcium, phosphate or vitamin D metabolites.
F. Hannan, P. Newey, M. Whyte, R. Thakker   +3 more
semanticscholar   +1 more source

Patient‐Level Barriers and Facilitators to Inpatient Physical Therapy in Adolescents and Young Adults With a Hematological Malignancy: A Qualitative Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Despite their increased risk for functional impairment resulting from cancer and its treatments, few adolescents and young adults (AYAs) with a hematological malignancy receive the recommended or therapeutic dose of exercise per week during inpatient hospitalizations.
Jennifer A. Kelleher, Jennifer L. Bernstein, Katia M. Crisler, Julia K. Herriott, Kimberly L. Klages, Robin E. Norris, Mariann L. Strenk, Sarah E. Bills, Meghan E. McGrady   +8 more
wiley   +1 more source

An Unusual Stress Fracture in an Archer with Hypophosphatasia

Case Reports in Orthopedics, 2013
We report a 45-year-old male archer with stress fracture in his left ulna on the background of adult type of hypophosphatasia. The patient presented to several medical centers for pain around the left elbow and received medical treatment upon diagnosis ...
Umut Yavuz, Sami Sökücü, Bilal Demir, Evren Akpınar, Osman Lapçin, Yunus Atıcı, Yavuz Kabukçuoğlu   +6 more
doaj   +1 more source

Characterizing Parental Concerns About Lasting Impacts of Treatment in Children With B‐Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background B‐acute lymphoblastic leukemia (B‐ALL) is the most common pediatric cancer, and while most children in high‐resource settings are cured, therapy carries risks for long‐term toxicities. Understanding parents’ concerns about these late effects is essential to guide anticipatory support and inform evolving therapeutic approaches ...
Kellee N. Parker, Sarah W. Alexander, Lisa M. Jacola, Kimberly A. Buff, Kyobin Hwang, Elham Hashemi, Gregory Stoddard, Lindsay A. Jibb   +7 more
wiley   +1 more source

Type 2 diabetes affects bone cells precursors and bone turnover

BMC Endocrine Disorders, 2018
Background Here we study the effect of type 2 diabetes (T2DM) on bone cell precursors, turnover and cytokines involved in the control of bone cell formation and activity. Methods We enrolled in the study 21 T2DM women and 21 non diabetic controls matched
Francesca Sassi, Ilaria Buondonno, Chiara Luppi, Elena Spertino, Emanuela Stratta, Marco Di Stefano, Marco Ravazzoli, Gianluca Isaia, Marina Trento, Pietro Passera, Massimo Porta, Giovanni Carlo Isaia, Patrizia D’Amelio   +12 more
doaj   +1 more source

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 [PDF]

, 2019
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic ...
Ajana, F, Arribas, JR, Bailey, J, Benson, P, Berenguer, J, Bhatti, L, Blaxhult, A, Brar, I, Bredeek, UF, Brinson, C, Brown, Kimberley, Brunetta, J, Casado, J, Clarke, A, Conway, B, Cotte, L, Crofoot, G, Cunningham, D, Cunningham, Douglas, de Vente, J, De Wit, S, De Wit, Stéphane, DeJesus, E, Dietz, C, Dretler, R, Eron, J, Eron, Joseph J, Fehr, J, Felizarta, F, Fichtenbaum, C, Flamholc, L, Florence, E, Galindo, MJ, Gallant, J, Gasiorowski, J, Gatell, JM, Gathe, J, Gazzard, BG, Girardy, P-M, Gisslèn, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henn, S, Henry, WK, Horban, A, Hufkens, Veerle, Huhn, G, Iribarren, JA, Jain, M, Jezorwski, John, Johnson, MA, Katlama, C, Klein, M, Knobel, H, Lathouwers, Erkki, Lucasti, C, Martorell, C, McDonald, C, Mills, A, Molina, J-M, Morales-Ramirez, J, Mounzer, K, Moutschen, M, Murphy, D, Nahass, R, Negredo, E, Olivet, H, Opsomer, Magda, Orkin, C, Orkin, Chloe, Osiyemi, O, Perez-Valero, I, Petrovic, Romana, Piekarska, A, Pineda, JA, Podzamczer, D, Poizot-Martin, I, Portilla Sogorb, J, Post, F, Post, Frank A, Prelutsky, D, Pulido, F, Pulido, Federico, Rachlis, A, Raffi, F, Ramgopal, M, Rashbaum, B, Rauch, A, Rey, D, Reynes, J, Ricart, C, Richmond, G, Rivero, A, Ruane, P, Santos Gil, I, Scarsella, A, Scribner, A, Shafran, S, Shalit, P, Shamblaw, D, Slim, J, Stoeckle, M, Tashima, K, Teicher, E, Thalme, A, Ustianowski, A, Van Landuyt, Erika, Van Wijngaerden, E, Vandekerckhove, Linos, Vandercam, B, Voskuhl, G, Walmsley, S, Ward, D, Waters, L, Wilkin, A, Witor, A, Yazdanpanah, Y   +118 more
core   +2 more sources

The Paget's disease of bone risk gene PML is a negative regulator of osteoclast differentiation and bone resorption [PDF]

, 2022
Sachin Wani, Anna Daroszewska, Donald M. Salter, Rob vanʼt Hof, Stuart H. Ralston, Omar Albagha   +5 more
openalex   +1 more source

Circular RNAs and hereditary bone diseases.

Intractable & Rare Diseases Research, 2018
Circular RNA (circRNA) is a non-linear form of RNA derived from exonic, intronic, and exon-intron gene regions. circRNAs are characterized by covalent closed loops, highly stable nuclease resistance, and specific expression in species and developmental ...
Naixiang Zhai, Yan-qin Lu, Yanzhou Wang, X. Ren, Jinxiang Han   +4 more
semanticscholar   +1 more source